A phase I clinical trial of intrapleural adenoviral-mediated interferon-beta (IFN-beta) gene transfer [BG00001] for pleural malignancies
Latest Information Update: 31 Mar 2023
Price :
$35 *
At a glance
- Drugs BG 00001 (Primary)
- Indications Cancer metastases; Malignant-mesothelioma
- Focus Adverse reactions
- 12 May 2020 Status changed from active, no longer recruiting to completed.
- 11 Jul 2007 New trial record.